Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-06-03
1999-03-16
Ambrose, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514114, 514439, 549 40, 558 14, 558175, 558446, 558483, 558484, 558485, 558 87, 558143, A61K 3121, A61K 3139, A61K 3166, C07C20304
Patent
active
058831223
ABSTRACT:
Aliphatic nitrate esters having a sulfur or phosphorus atom .beta. or .gamma. to a nitrate group and their congeners having efficacy as neuroprotective agents are described. Preferred nitrate esters may be synthesized by nitration of a 3-bromo-1,2-propanediol, and subsequent reaction to yield the desired mono-, di- or tetra-nitrate ester.
REFERENCES:
patent: 4801596 (1989-01-01), Simon et al.
patent: 4863949 (1989-09-01), Simon et al.
patent: 5049694 (1991-09-01), Bron et al.
patent: 5284872 (1994-02-01), Sandrock et al.
patent: 5428061 (1995-06-01), Sandrock et al.
Yang, K., Artz, J.D., Lock, J., Sanchez, C., Bennett, B.M., Fraser, A.B., and Thatcher, G.R.J., "Synthesis of novel organic nitrate esters: guanylate cyclase activation and tissue relaxation", J. Chem. Soc., Perkin Trans. 1, 1073-1075 (1996).
Artz, J.D., Yang, K., Lock, J., Sanchez, C., Bennett, B.M., and Thatcher, G.R.J., "Reactivity of thionitrate esters: putative intermediates in nitrovasodilator activity", Chem. Commun. 927-928 (1996).
Bennett, B.M., McDonald, B.J., Nigam, R., and Simon, W.C., "Biotransformation of organic nitrates and vascular smooth muscle cell function", Trends in Pharmacol. Sci. 15: 245-249 (1994).
Cameron, D.R., Borrajo, A.M.P., Bennett, B.M., and Thatcher, G.R.J., "Organic nitrates, thionitrates, peroxynitrites, and nitric oxide: a molecular orbital study of RXNO.sub.2 .rarw..fwdarw.RXONO (X=O,S) rearrangement, a reaction of potential biological significance", Can. J. Chem. 73: 1627-1638 (1995).
Chong, S., and Fung, H.-L., "Biological and pharmacological interactions between nitroglycerin and thiols. Effects of thiol structure on nitric oxide generation and tolerance reversal", Biochem. Pharm., 42: 1433-1439 (1991).
Feelisch, M., "Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators", Eur. Heart J. 14(Supp. 1): 123-132 (1993).
Fung, H.-L., "Nitrate therapy: is there an optimal substance and formulation", Eur. Heart J., 12(Supp A):9-12 (1991).
Kojda, G., Feelisch, M., and Noack, E., "Sulfhydryl-containing nitrate esters: a new class of nitric oxide donors", Cardiovasc. Drug Rev. 13: 275-288 (1995).
Yeates, R.A., "Possible mechanisms of activation of soluble guanylate cyclase by organic nitrates", Arzneim-Forsch./Drug Res. 42(II): 1314-1317 (1992).
Yeates, R.A., Laufen, H., and Leitold, M., "The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates.", Mol. Pharm. 28: 555-559 (1985).
Zanzinger, J., Feelisch, M., and Bassenge, E., "Novel organic nitrates are potent dilators of large coronary arteries with reduced development of tolerance during long-term infusion in dogs: role of the Sulfhydryl moiety", J. Cardiovas. Pharm. 23: 772-778 (1994).
Bennett Brian M.
Boegman Roland J.
Jhamandas Khem
Reynolds James N.
Thatcher Gregory R. J.
Ambrose Michael G.
Hicks Richard J.
Queen's University at Kingston
Steeg Carol Miernicki
LandOfFree
Nitrate esters and their use for neurological conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrate esters and their use for neurological conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrate esters and their use for neurological conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-818088